Australia markets closed

Seres Therapeutics, Inc. (MCRB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.1400-0.0900 (-7.32%)
At close: 04:00PM EST
1.1800 +0.04 (+3.51%)
After hours: 08:00PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 157.69M
Enterprise value 200.06M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.22
Price/book (mrq)63.84
Enterprise value/revenue 1.57
Enterprise value/EBITDA -1.61

Trading information

Stock price history

Beta (5Y monthly) 2.27
52-week change 3-77.22%
S&P500 52-week change 328.87%
52-week high 36.8700
52-week low 30.9100
50-day moving average 31.1947
200-day moving average 32.6916

Share statistics

Avg vol (3-month) 34.72M
Avg vol (10-day) 33.85M
Shares outstanding 5129.26M
Implied shares outstanding 6139.46M
Float 8100.61M
% held by insiders 16.65%
% held by institutions 169.54%
Shares short (15 Feb 2024) 415.59M
Short ratio (15 Feb 2024) 44.58
Short % of float (15 Feb 2024) 422.69%
Short % of shares outstanding (15 Feb 2024) 412.06%
Shares short (prior month 12 Jan 2024) 417.55M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2022
Most-recent quarter (mrq)30 Sept 2023


Profit margin -111.03%
Operating margin (ttm)-15,294.52%

Management effectiveness

Return on assets (ttm)-25.16%
Return on equity (ttm)-538.57%

Income statement

Revenue (ttm)127.24M
Revenue per share (ttm)1.00
Quarterly revenue growth (yoy)-91.00%
Gross profit (ttm)N/A
EBITDA -130.53M
Net income avi to common (ttm)-141.27M
Diluted EPS (ttm)-1.0400
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)169.91M
Total cash per share (mrq)1.32
Total debt (mrq)212.28M
Total debt/equity (mrq)N/A
Current ratio (mrq)2.71
Book value per share (mrq)-0.12

Cash flow statement

Operating cash flow (ttm)-122.75M
Levered free cash flow (ttm)-91.02M